Worldwide susceptibility rates of Neisseria gonorrhoeae isolates to cefixime and cefpodoxime: a systematic review and meta-analysis
Neisseria gonorrhoeae (NG) infection is a serious public health problem. The third-generation extended-spectrum cephalosporins (ESCs) have been used as the first-line treatment for NG infection for almost three decades. However, in recent years, treatment failures with the oral third-generation ESCs...
Gespeichert in:
| Veröffentlicht in: | PloS one 2014-01, Vol.9 (1), p.e87849-e87849 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e87849 |
|---|---|
| container_issue | 1 |
| container_start_page | e87849 |
| container_title | PloS one |
| container_volume | 9 |
| creator | Yu, Rui-xing Yin, Yueping Wang, Guan-qun Chen, Shao-chun Zheng, Bing-jie Dai, Xiu-qin Han, Yan Li, Qi Zhang, Guo-yi Chen, Xiangsheng |
| description | Neisseria gonorrhoeae (NG) infection is a serious public health problem. The third-generation extended-spectrum cephalosporins (ESCs) have been used as the first-line treatment for NG infection for almost three decades. However, in recent years, treatment failures with the oral third-generation ESCs have been reported worldwide. This study aimed to estimate worldwide susceptibility rates of NG to cefixime and cefpodoxime by analyzing data from all relevant published studies.
Two researchers independently searched five databases to identify studies on susceptibilities of NG to cefixime and cefpodoxime published between January 1, 1984 and October 15, 2012. A fixed-effect model was used to perform group analysis, and a χ2 test was employed to make subgroup comparison. Publication bias was assessed with the Begg rank correlation test. The pooled susceptibility rate of NG isolates to cefixime was 99.8% (95% CI: 99.7%-99.8%). The cefixime susceptibility rate of NG isolates from men was significantly lower than that from patients without information of gender or from men and women; the susceptibility rate of NG isolates from Asia was significantly lower than that from other continents; and the susceptibility rate of NG isolates collected before or during 2003 was significantly higher than that after 2003. The pooled susceptibility rate of NG isolates to cefpodoxime was 92.8% (95% CI: 89.0%-95.3%), which was lower than that to cefixime (92.8% vs. 99.8%, χ2 = 951.809, P |
| doi_str_mv | 10.1371/journal.pone.0087849 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1977449313</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A478832215</galeid><doaj_id>oai_doaj_org_article_99a306244d1b4a389c15e4b150590971</doaj_id><sourcerecordid>A478832215</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-8265318682bf8126a7572268197b40aaf0935faaf05d1f81117c354d22791af13</originalsourceid><addsrcrecordid>eNqNk0tv1DAQxyMEoqXwDRBEQkJw2MWPPGwOSFXFY6WKSjyP1iSZ7HqVxFvbabtnvjjOblptUA8oB8f27z_j-dsTRc8pmVOe03dr09sOmvnGdDgnROQikQ-iYyo5m2WM8IcH_0fRE-fWhKRcZNnj6IgliRSMsuPoz29jm-paVxi73pW48brQjfbb2IJHF5s6_oraObQa4qXpjLUrg4CxdqbZEd7EJdb6RrcYQ1cNk42pzDB_H0Psts5jC16XscUrjdc7qEUPMwjH3zrtnkaPamgcPhvHk-jnp48_zr7Mzi8-L85Oz2dlJpmfCZalnIpMsKIWlGWQpzljmaAyLxICUBPJ03oY04oGgtK85GlSMZZLCjXlJ9HLfdxNY5wa_XMq6PPgB6c8EIs9URlYq43VLditMqDVbsHYpQIbSmlQSQmcZMHIihYJcCFLmmJS0JSkksh8yPZhzNYXLVYldt5CMwk63en0Si3NleJBz1IWArwZA1hz2aPzqtXhhpoGOjR9OHciJWVJnsmAvvoHvb-6kVpCKEB3tQl5yyGoOk1yIThjNA3U_B4qfBW2ugyPrdZhfSJ4OxEExuONX0LvnFp8__b_7MWvKfv6gF0hNH4VHl3vtencFEz2YGmNcxbrO5MpUUOv3Lqhhl5RY68E2YvDC7oT3TYH_wu84Q8K</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1977449313</pqid></control><display><type>article</type><title>Worldwide susceptibility rates of Neisseria gonorrhoeae isolates to cefixime and cefpodoxime: a systematic review and meta-analysis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS)</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Yu, Rui-xing ; Yin, Yueping ; Wang, Guan-qun ; Chen, Shao-chun ; Zheng, Bing-jie ; Dai, Xiu-qin ; Han, Yan ; Li, Qi ; Zhang, Guo-yi ; Chen, Xiangsheng</creator><contributor>Chaturvedi, Vishnu</contributor><creatorcontrib>Yu, Rui-xing ; Yin, Yueping ; Wang, Guan-qun ; Chen, Shao-chun ; Zheng, Bing-jie ; Dai, Xiu-qin ; Han, Yan ; Li, Qi ; Zhang, Guo-yi ; Chen, Xiangsheng ; Chaturvedi, Vishnu</creatorcontrib><description>Neisseria gonorrhoeae (NG) infection is a serious public health problem. The third-generation extended-spectrum cephalosporins (ESCs) have been used as the first-line treatment for NG infection for almost three decades. However, in recent years, treatment failures with the oral third-generation ESCs have been reported worldwide. This study aimed to estimate worldwide susceptibility rates of NG to cefixime and cefpodoxime by analyzing data from all relevant published studies.
Two researchers independently searched five databases to identify studies on susceptibilities of NG to cefixime and cefpodoxime published between January 1, 1984 and October 15, 2012. A fixed-effect model was used to perform group analysis, and a χ2 test was employed to make subgroup comparison. Publication bias was assessed with the Begg rank correlation test. The pooled susceptibility rate of NG isolates to cefixime was 99.8% (95% CI: 99.7%-99.8%). The cefixime susceptibility rate of NG isolates from men was significantly lower than that from patients without information of gender or from men and women; the susceptibility rate of NG isolates from Asia was significantly lower than that from other continents; and the susceptibility rate of NG isolates collected before or during 2003 was significantly higher than that after 2003. The pooled susceptibility rate of NG isolates to cefpodoxime was 92.8% (95% CI: 89.0%-95.3%), which was lower than that to cefixime (92.8% vs. 99.8%, χ2 = 951.809, P<0.01).
The susceptibility rate of NG isolates to cefixime varied with the gender of patients and geographical location from which NG isolates were collected, and declined with time. The reported lower susceptibility rate of NG isolates to cefixime and associated treatment failures, as well as the emergence of NG strains with cephalosporin resistance call for the more effective control of NG infection and the development of new antibiotics.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0087849</identifier><identifier>PMID: 24498212</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Analysis ; Anti-Bacterial Agents - therapeutic use ; Antibiotics ; Antimicrobial agents ; Biology ; Cefixime ; Cefixime - therapeutic use ; Cefpodoxime ; Ceftizoxime - analogs & derivatives ; Ceftizoxime - therapeutic use ; Cephalosporins ; Condoms ; Continents ; Data processing ; Dermatology ; Drug resistance ; Failure ; Female ; Geographical distribution ; Gonorrhea ; Gonorrhea - drug therapy ; Gonorrhea - epidemiology ; Gonorrhea - microbiology ; Health aspects ; Humans ; Infection ; Infections ; Male ; Medical laboratories ; Medical research ; Medicine ; Meta-analysis ; Molecular biology ; Neisseria gonorrhoeae ; Neisseria gonorrhoeae - isolation & purification ; Neisseria gonorrhoeae - metabolism ; Neisseria gonorrhoeae - pathogenicity ; Patients ; Penicillin ; Public health ; Rankings ; Researchers ; Skin diseases ; Studies ; Surveillance ; Systematic review</subject><ispartof>PloS one, 2014-01, Vol.9 (1), p.e87849-e87849</ispartof><rights>COPYRIGHT 2014 Public Library of Science</rights><rights>2014 Yu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2014 Yu et al 2014 Yu et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-8265318682bf8126a7572268197b40aaf0935faaf05d1f81117c354d22791af13</citedby><cites>FETCH-LOGICAL-c692t-8265318682bf8126a7572268197b40aaf0935faaf05d1f81117c354d22791af13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909252/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909252/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793,79472,79473</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24498212$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Chaturvedi, Vishnu</contributor><creatorcontrib>Yu, Rui-xing</creatorcontrib><creatorcontrib>Yin, Yueping</creatorcontrib><creatorcontrib>Wang, Guan-qun</creatorcontrib><creatorcontrib>Chen, Shao-chun</creatorcontrib><creatorcontrib>Zheng, Bing-jie</creatorcontrib><creatorcontrib>Dai, Xiu-qin</creatorcontrib><creatorcontrib>Han, Yan</creatorcontrib><creatorcontrib>Li, Qi</creatorcontrib><creatorcontrib>Zhang, Guo-yi</creatorcontrib><creatorcontrib>Chen, Xiangsheng</creatorcontrib><title>Worldwide susceptibility rates of Neisseria gonorrhoeae isolates to cefixime and cefpodoxime: a systematic review and meta-analysis</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Neisseria gonorrhoeae (NG) infection is a serious public health problem. The third-generation extended-spectrum cephalosporins (ESCs) have been used as the first-line treatment for NG infection for almost three decades. However, in recent years, treatment failures with the oral third-generation ESCs have been reported worldwide. This study aimed to estimate worldwide susceptibility rates of NG to cefixime and cefpodoxime by analyzing data from all relevant published studies.
Two researchers independently searched five databases to identify studies on susceptibilities of NG to cefixime and cefpodoxime published between January 1, 1984 and October 15, 2012. A fixed-effect model was used to perform group analysis, and a χ2 test was employed to make subgroup comparison. Publication bias was assessed with the Begg rank correlation test. The pooled susceptibility rate of NG isolates to cefixime was 99.8% (95% CI: 99.7%-99.8%). The cefixime susceptibility rate of NG isolates from men was significantly lower than that from patients without information of gender or from men and women; the susceptibility rate of NG isolates from Asia was significantly lower than that from other continents; and the susceptibility rate of NG isolates collected before or during 2003 was significantly higher than that after 2003. The pooled susceptibility rate of NG isolates to cefpodoxime was 92.8% (95% CI: 89.0%-95.3%), which was lower than that to cefixime (92.8% vs. 99.8%, χ2 = 951.809, P<0.01).
The susceptibility rate of NG isolates to cefixime varied with the gender of patients and geographical location from which NG isolates were collected, and declined with time. The reported lower susceptibility rate of NG isolates to cefixime and associated treatment failures, as well as the emergence of NG strains with cephalosporin resistance call for the more effective control of NG infection and the development of new antibiotics.</description><subject>Analysis</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Biology</subject><subject>Cefixime</subject><subject>Cefixime - therapeutic use</subject><subject>Cefpodoxime</subject><subject>Ceftizoxime - analogs & derivatives</subject><subject>Ceftizoxime - therapeutic use</subject><subject>Cephalosporins</subject><subject>Condoms</subject><subject>Continents</subject><subject>Data processing</subject><subject>Dermatology</subject><subject>Drug resistance</subject><subject>Failure</subject><subject>Female</subject><subject>Geographical distribution</subject><subject>Gonorrhea</subject><subject>Gonorrhea - drug therapy</subject><subject>Gonorrhea - epidemiology</subject><subject>Gonorrhea - microbiology</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Infection</subject><subject>Infections</subject><subject>Male</subject><subject>Medical laboratories</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Meta-analysis</subject><subject>Molecular biology</subject><subject>Neisseria gonorrhoeae</subject><subject>Neisseria gonorrhoeae - isolation & purification</subject><subject>Neisseria gonorrhoeae - metabolism</subject><subject>Neisseria gonorrhoeae - pathogenicity</subject><subject>Patients</subject><subject>Penicillin</subject><subject>Public health</subject><subject>Rankings</subject><subject>Researchers</subject><subject>Skin diseases</subject><subject>Studies</subject><subject>Surveillance</subject><subject>Systematic review</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk0tv1DAQxyMEoqXwDRBEQkJw2MWPPGwOSFXFY6WKSjyP1iSZ7HqVxFvbabtnvjjOblptUA8oB8f27z_j-dsTRc8pmVOe03dr09sOmvnGdDgnROQikQ-iYyo5m2WM8IcH_0fRE-fWhKRcZNnj6IgliRSMsuPoz29jm-paVxi73pW48brQjfbb2IJHF5s6_oraObQa4qXpjLUrg4CxdqbZEd7EJdb6RrcYQ1cNk42pzDB_H0Psts5jC16XscUrjdc7qEUPMwjH3zrtnkaPamgcPhvHk-jnp48_zr7Mzi8-L85Oz2dlJpmfCZalnIpMsKIWlGWQpzljmaAyLxICUBPJ03oY04oGgtK85GlSMZZLCjXlJ9HLfdxNY5wa_XMq6PPgB6c8EIs9URlYq43VLditMqDVbsHYpQIbSmlQSQmcZMHIihYJcCFLmmJS0JSkksh8yPZhzNYXLVYldt5CMwk63en0Si3NleJBz1IWArwZA1hz2aPzqtXhhpoGOjR9OHciJWVJnsmAvvoHvb-6kVpCKEB3tQl5yyGoOk1yIThjNA3U_B4qfBW2ugyPrdZhfSJ4OxEExuONX0LvnFp8__b_7MWvKfv6gF0hNH4VHl3vtencFEz2YGmNcxbrO5MpUUOv3Lqhhl5RY68E2YvDC7oT3TYH_wu84Q8K</recordid><startdate>20140131</startdate><enddate>20140131</enddate><creator>Yu, Rui-xing</creator><creator>Yin, Yueping</creator><creator>Wang, Guan-qun</creator><creator>Chen, Shao-chun</creator><creator>Zheng, Bing-jie</creator><creator>Dai, Xiu-qin</creator><creator>Han, Yan</creator><creator>Li, Qi</creator><creator>Zhang, Guo-yi</creator><creator>Chen, Xiangsheng</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20140131</creationdate><title>Worldwide susceptibility rates of Neisseria gonorrhoeae isolates to cefixime and cefpodoxime: a systematic review and meta-analysis</title><author>Yu, Rui-xing ; Yin, Yueping ; Wang, Guan-qun ; Chen, Shao-chun ; Zheng, Bing-jie ; Dai, Xiu-qin ; Han, Yan ; Li, Qi ; Zhang, Guo-yi ; Chen, Xiangsheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-8265318682bf8126a7572268197b40aaf0935faaf05d1f81117c354d22791af13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Analysis</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Biology</topic><topic>Cefixime</topic><topic>Cefixime - therapeutic use</topic><topic>Cefpodoxime</topic><topic>Ceftizoxime - analogs & derivatives</topic><topic>Ceftizoxime - therapeutic use</topic><topic>Cephalosporins</topic><topic>Condoms</topic><topic>Continents</topic><topic>Data processing</topic><topic>Dermatology</topic><topic>Drug resistance</topic><topic>Failure</topic><topic>Female</topic><topic>Geographical distribution</topic><topic>Gonorrhea</topic><topic>Gonorrhea - drug therapy</topic><topic>Gonorrhea - epidemiology</topic><topic>Gonorrhea - microbiology</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Infection</topic><topic>Infections</topic><topic>Male</topic><topic>Medical laboratories</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Meta-analysis</topic><topic>Molecular biology</topic><topic>Neisseria gonorrhoeae</topic><topic>Neisseria gonorrhoeae - isolation & purification</topic><topic>Neisseria gonorrhoeae - metabolism</topic><topic>Neisseria gonorrhoeae - pathogenicity</topic><topic>Patients</topic><topic>Penicillin</topic><topic>Public health</topic><topic>Rankings</topic><topic>Researchers</topic><topic>Skin diseases</topic><topic>Studies</topic><topic>Surveillance</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yu, Rui-xing</creatorcontrib><creatorcontrib>Yin, Yueping</creatorcontrib><creatorcontrib>Wang, Guan-qun</creatorcontrib><creatorcontrib>Chen, Shao-chun</creatorcontrib><creatorcontrib>Zheng, Bing-jie</creatorcontrib><creatorcontrib>Dai, Xiu-qin</creatorcontrib><creatorcontrib>Han, Yan</creatorcontrib><creatorcontrib>Li, Qi</creatorcontrib><creatorcontrib>Zhang, Guo-yi</creatorcontrib><creatorcontrib>Chen, Xiangsheng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yu, Rui-xing</au><au>Yin, Yueping</au><au>Wang, Guan-qun</au><au>Chen, Shao-chun</au><au>Zheng, Bing-jie</au><au>Dai, Xiu-qin</au><au>Han, Yan</au><au>Li, Qi</au><au>Zhang, Guo-yi</au><au>Chen, Xiangsheng</au><au>Chaturvedi, Vishnu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Worldwide susceptibility rates of Neisseria gonorrhoeae isolates to cefixime and cefpodoxime: a systematic review and meta-analysis</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2014-01-31</date><risdate>2014</risdate><volume>9</volume><issue>1</issue><spage>e87849</spage><epage>e87849</epage><pages>e87849-e87849</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Neisseria gonorrhoeae (NG) infection is a serious public health problem. The third-generation extended-spectrum cephalosporins (ESCs) have been used as the first-line treatment for NG infection for almost three decades. However, in recent years, treatment failures with the oral third-generation ESCs have been reported worldwide. This study aimed to estimate worldwide susceptibility rates of NG to cefixime and cefpodoxime by analyzing data from all relevant published studies.
Two researchers independently searched five databases to identify studies on susceptibilities of NG to cefixime and cefpodoxime published between January 1, 1984 and October 15, 2012. A fixed-effect model was used to perform group analysis, and a χ2 test was employed to make subgroup comparison. Publication bias was assessed with the Begg rank correlation test. The pooled susceptibility rate of NG isolates to cefixime was 99.8% (95% CI: 99.7%-99.8%). The cefixime susceptibility rate of NG isolates from men was significantly lower than that from patients without information of gender or from men and women; the susceptibility rate of NG isolates from Asia was significantly lower than that from other continents; and the susceptibility rate of NG isolates collected before or during 2003 was significantly higher than that after 2003. The pooled susceptibility rate of NG isolates to cefpodoxime was 92.8% (95% CI: 89.0%-95.3%), which was lower than that to cefixime (92.8% vs. 99.8%, χ2 = 951.809, P<0.01).
The susceptibility rate of NG isolates to cefixime varied with the gender of patients and geographical location from which NG isolates were collected, and declined with time. The reported lower susceptibility rate of NG isolates to cefixime and associated treatment failures, as well as the emergence of NG strains with cephalosporin resistance call for the more effective control of NG infection and the development of new antibiotics.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>24498212</pmid><doi>10.1371/journal.pone.0087849</doi><tpages>e87849</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2014-01, Vol.9 (1), p.e87849-e87849 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1977449313 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS); PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Analysis Anti-Bacterial Agents - therapeutic use Antibiotics Antimicrobial agents Biology Cefixime Cefixime - therapeutic use Cefpodoxime Ceftizoxime - analogs & derivatives Ceftizoxime - therapeutic use Cephalosporins Condoms Continents Data processing Dermatology Drug resistance Failure Female Geographical distribution Gonorrhea Gonorrhea - drug therapy Gonorrhea - epidemiology Gonorrhea - microbiology Health aspects Humans Infection Infections Male Medical laboratories Medical research Medicine Meta-analysis Molecular biology Neisseria gonorrhoeae Neisseria gonorrhoeae - isolation & purification Neisseria gonorrhoeae - metabolism Neisseria gonorrhoeae - pathogenicity Patients Penicillin Public health Rankings Researchers Skin diseases Studies Surveillance Systematic review |
| title | Worldwide susceptibility rates of Neisseria gonorrhoeae isolates to cefixime and cefpodoxime: a systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T01%3A48%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Worldwide%20susceptibility%20rates%20of%20Neisseria%20gonorrhoeae%20isolates%20to%20cefixime%20and%20cefpodoxime:%20a%20systematic%20review%20and%20meta-analysis&rft.jtitle=PloS%20one&rft.au=Yu,%20Rui-xing&rft.date=2014-01-31&rft.volume=9&rft.issue=1&rft.spage=e87849&rft.epage=e87849&rft.pages=e87849-e87849&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0087849&rft_dat=%3Cgale_plos_%3EA478832215%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1977449313&rft_id=info:pmid/24498212&rft_galeid=A478832215&rft_doaj_id=oai_doaj_org_article_99a306244d1b4a389c15e4b150590971&rfr_iscdi=true |